Financial Performance - Q3 2025 revenue reached $92 million, a 37% increase compared to Q3 2024[11] - Adjusted EBITDA improved by $39 million in Q3 2025 compared to Q3 2024[11] - Charging Network Gross Margin improved by 110 bps in Q3 2025[58] - Adjusted General and Administrative Expenses as a Percentage of Revenue decreased by 550 bps in Q3 2025[59] - Adjusted EBITDA loss improved 44% in Q3 2025[59] Operational Growth - Stalls in operation increased by 25%, reaching 4,590[11] - Public network throughput increased 13x[58] - The company anticipates Adjusted EBITDA breakeven in Q4 2025[64] Strategic Initiatives - The company closed a commercial bank facility and received the first two draws[13] - The company launched additional sites with J3400 (NACS) connectors[13] - The company expects 40% capital offsets for 2025 vintage capex per stall[42]

Peak Trial Results - The combination of Bezuclastinib + Sunitinib demonstrates a 50% reduction in the risk of progression or death compared to Sunitinib alone in patients with GIST [25, 47] - Median Progression-Free Survival (PFS) for Bezuclastinib + Sunitinib is 16.5 months, compared to 9.2 months for Sunitinib alone (p<0.0001) [26, 47] - Objective Response Rate (ORR) per BICR for Bezuclastinib + Sunitinib is 45.6%, compared to 25.8% for Sunitinib alone (p<0.0001) [28, 47] - Complete Response (CR) rate in the Bezuclastinib + Sunitinib arm is 6.4%, compared to 1.9% in the Sunitinib arm [28] Safety and Tolerability - The incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) is similar between the Bezuclastinib + Sunitinib and Sunitinib arms [29, 30] - Grade 3+ TRAEs occurred in 71.6% of patients in the Bezuclastinib + Sunitinib arm and 52.4% in the Sunitinib arm [29] - No TRAEs leading to death were reported in the Bezuclastinib + Sunitinib arm, while 0.5% of patients in the Sunitinib arm experienced TRAEs leading to death [29] Market and Regulatory Strategy - The company plans an NDA submission for Bezuclastinib in imatinib-resistant or intolerant GIST in the first half of 2026 based on the Peak trial results [47, 54] - An active Expanded Access Program is available, allowing immediate access to the Bezuclastinib combination for 2L patients with GIST [47, 48] - The estimated aggregate global annual sales opportunity for Bezuclastinib across indications is >$7.5 billion [57]

Scaling new heights in the fight against heart disease November 10, 2025 Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qua ...

Q3 2025 Financial Performance - Kaspi.kz's Total Payment Value (TPV) increased by 18% year-over-year (YoY)[10] - Kaspi.kz's Revenue increased by 10% YoY[10] - Kaspi.kz's Net Income increased by 12% YoY[10] Marketplace Platform Growth - Marketplace purchases increased by 36% YoY in 3Q'25[93] - Excluding smartphones, Marketplace Gross Merchandise Value (GMV) increased by 20% YoY[96] - e-Commerce GMV increased by 25% YoY excluding smartphones[99] Fintech Platform Performance - Total Finance Value (TFV) increased by 16% YoY[114] - Average net loan portfolio increased by 30% YoY[117] - Deposits increased by 18% YoY[117] - Fintech revenue increased by 24% YoY adjusting for higher interest rates[122] Hepsiburada Performance - Hepsiburada purchases increased by 16% in 3Q'25[64, 128] - Hepsiburada GMV increased by 15% in 3Q'25[131] - Hepsiburada revenue increased by 22% YoY[134]

BPL-003 Phase 2b Clinical Trial Results - The open-label extension of the BPL-003 Phase 2b clinical trial demonstrated additional and durable antidepressant effects after a second dose[11] - Patients who received an active dose (either 8 mg or 12 mg) of BPL-003 in the core study achieved a response rate of 63% and a remission rate of 48% at Week 8 (Week 16 of the Phase 2b clinical trial)[11] - In the core study, statistically significant MADRS difference was observed at Day 29 (Week 4) following a single 8 mg or 12 mg dose vs 0.3 mg[21] - In the core study, 8 mg dose demonstrated comparable efficacy to 12 mg, suggesting it may be sufficient to achieve maximal therapeutic benefit[21] - In the OLE study, patients who received an active dose in the core study showed a mean reduction in MADRS score of 19.0 points at Day 57 compared to baseline at the start of the Phase 2b clinical trial[36] - In the OLE study, responder rates continued to improve following a second dose of BPL-003[37] - In the OLE study, remission rates continued to improve following a second dose of BPL-003[40] Safety and Tolerability - BPL-003 was generally well-tolerated, with the majority of TEAEs occurring on the day of dosing, classified as mild or moderate, and transient in nature[11] - In the core study, 78% of participants experienced any TEAE[24] - In the OLE study, 86% of participants experienced any TEAE[43] Market Opportunity - Spravato achieved blockbuster status and established the 2-hour in-clinic interventional psychiatry treatment paradigm[50] - Spravato reported global annual sales of $1.047 billion in Q1-Q3 2025[51]

Financial Performance & Acquisitions - Strata's Q3 2025 revenue reached $493 million, a 37% year-over-year increase, with 29% organic growth excluding the Keystone acquisition[5] - The acquisition of Keystone Perfusion contributed approximately $28 million to Strata's Q3 2025 revenue[6] - Adjusted EBITDA for Q3 2025 was $42 million, representing an 85% margin[5] - Strata sold its passenger business to Joby Aviation for $125 million[14] - Strata acquired Keystone Perfusion for $124 million upfront, with potential earn-outs of $23 million based on gross profit targets[15] Market Position & Growth Strategy - Strata estimates its market share to be approximately 30% in air logistics and 15% in ground logistics for organ transport[11] - The company is focused on expanding its transplant clinical services, particularly Normothermic Regional Perfusion (NRP), driven by a 20%+ CAGR in Donation after Circulatory Death (DCD) donors[43] - Strata aims to increase aircraft utilization and improve operating costs by expanding into other time-critical logistics verticals[55] Organ Transplant Trends - The distance of heart, liver, and lung transplants has increased by 64% from 2018 to 2024 due to regulatory changes and new technologies[39] - Normothermic Regional Perfusion (NRP) penetration of DCD donors has increased to approximately 40% by Q3 2025[43] - U S heart, liver, and lung transplants have grown at a CAGR of 38% from 2010-2024[27]

Q3 2025 Highlights - Dole's broadly based business model delivered a good Q3 2025 result, in line with market expectations[9] - The company completed the sale of its Fresh Vegetable division at the beginning of August for $140 million[9] - The board authorized share repurchases of up to $100 million[9] Financial Performance - Q3 2025 revenue increased to $2,279 million, compared to $2,062 million in Q3 2024[25] - Income from continuing operations for Q3 2025 was $241 million, up from $151 million in Q3 2024[25] - Net income attributable to Dole plc decreased to $51 million in Q3 2025, from $144 million in Q3 2024[25] - Adjusted EBITDA for Q3 2025 was $808 million, slightly down from $821 million in Q3 2024[25] Segment Results - Fresh Fruit revenue increased by 115% to $890 million, but Adjusted EBITDA decreased by 367% to $272 million due to higher sourcing costs[28] - Diversified Fresh Produce – EMEA revenue increased by 109% to $998 million, and Adjusted EBITDA increased by 342% to $407 million[32] - Diversified Fresh Produce – Americas & ROW revenue increased by 77% to $420 million, and Adjusted EBITDA increased by 462% to $129 million[37] FY'25 Outlook - The company is targeting the upper end of the $380-$390 million range for Adjusted EBITDA from continuing operations[46] - Routine capital expenditure for continuing operations is expected to be approximately $85 million[46]

LSEG Group Strategy and Performance - LSEG's diversified business model delivers strong financial performance, with 73% high-quality recurring revenues and structurally growing transactional revenues[26, 27] - LSEG has a track record of uncorrelated, all-weather growth, delivering Earnings per Share (EPS) CAGR of 15% and Dividend per Share (DPS) CAGR of 18% over the last 20 years[32, 34] - Free cash flow continues to trend upward, expected to hit £2.4 billion in 2025[36] - LSEG has delivered £292 million revenue and £562 million cost synergies[48] Data & Analytics Strategy and Monetization - Data & Analytics represents 47% of LSEG's £3.9 billion income in 2024[13] - LDAs are forecast to account for 17% of D&A ASV by the end of 2025[68] - Tick History is experiencing 39% p a growth in use[155] - Since 2021, D&A revenue growth has been accelerating, with >5 0% organic constant currency growth expected in FY2025[161] AI Strategy and Engineering Transformation - LSEG is the global 1 in real-time data[107] - LSEG's engineering transformation strategy focuses on Exceptional Talent, Common Platforms, and Product Discipline to accelerate product development and AI adoption[92, 93] - LSEG is transforming data onboarding and customer operations with AI, achieving results such as 9x faster content extraction and a 51% FTE reduction in the central sourcing team[127, 128] New Products and Services - ForexClear clears only 1% of the FX market, driven by FX Options and NDFs, which are subject to the Uncleared Margin Rules (UMR), generating over £50 million in annual revenue[380] - The Private Securities Market (PSM) charges companies an admission fee of £25,000 a year for access to 2 auctions, buyers will pay 0 75% on value of shares bought, sellers will pay 1% on value of shares sold[360, 361]

(NASDAQ: VIOT) Company Presentation Safe Harbor Statement This presentation has been prepared by Viomi Technology Co., Ltd ("Viomi" or the "Company") solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. This docu ...

Financial Performance - LINZESS U S net sales reached $315 million in Q3 2025, a 40% year-over-year increase, driven by improved net pricing and a 12% year-over-year growth in EUTRx demand[11] - Ironwood generated $40 million in GAAP net income and $82 million in adjusted EBITDA in Q3 2025[11] - The company's share of net profit from the LINZESS U S brand collaboration was $119 515 million for the three months ended September 30, 2025[15] - Ironwood's collaborative arrangements revenue was $119 646 million for the three months ended September 30, 2025[15] - Ironwood ended Q3 2025 with $140 million in cash and cash equivalents[11] Guidance and Expectations - Full-year LINZESS U S net sales guidance was raised to $860 - $890 million, and total revenue guidance to $290 - $310 million[11] - Adjusted EBITDA guidance was raised to greater than $135 million[11] LINZESS Performance - LINZESS extended unit (EUTRx) and new to brand (NBRx) prescriptions each grew 12% year-over-year in Q3 2025[12] - LINZESS U S net product sales as reported by AbbVie were $314 856 million for the three months ended September 30, 2025[15] Strategic Developments - In November 2025, the FDA approved LINZESS as the first drug for the treatment of children 7 years and older with irritable bowel syndrome with constipation (IBS-C)[11] - The company plans to align with the FDA in Q4 2025 on confirmatory Phase 3 trial design for Apraglutide, with trial initiation expected in 1H 2026[7]